SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing shares are under pressure after the FAA delayed 737 MAX 10 certification while reviewing a flight-management software glitch that can disrupt automated guidance in a specific landing scenario. Traders are divided: some call the issue manageable and the selloff excessive, while others see it as another sign of Boeings quality and management problems and worry about further certification delays.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas $2 billion convertible-equity investment and clinical collaboration with Summit have drawn attention, with traders viewing the deal as a major funding boost and vote of confidence in ivonescimab. Some speculate it could precede an acquisition, while others stress that it is an equity investmentnot a buyoutand that FDA approval and clinical outcomes remain uncertain.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks Phase 3 DAYBREAK study met its primary goals for two wet AMD drug candidates, with vision results comparable to Eylea and Zenkuda showing potential for longer dosing intervals; the results support a planned FDA filing. Traders cheered the clinical progress and discussed a possible short squeeze, while others questioned the rallys valuation and flagged financing, dilution, and regulatory risks.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for a U.S. Army program to develop next-generation 10 kV silicon-carbide power semiconductors is drawing attention as a technology and domestic-manufacturing validation. Traders are bullish on the longer-term potential and speculate about a short squeeze, while others note that the awards financial terms are undisclosed and near-term revenue is uncertain.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFAs move to let Fannie Mae and Freddie Mac use VantageScore alongside FICO scores has raised concerns that competition could weaken FICOs long-standing mortgage-scoring position and pricing power. Traders debate whether the shift signals lasting damage to the companys moat or an overreaction, with some seeing a buying opportunity while others expect further pressure.

Stellar is an open-source, decentralized network co-founded in 2014 by Jed McCaleb and Joyce Kim to facilitate the fast and low-cost transfer of value across different currencies and assets globally. Managed by the non-profit Stellar Development Foundation, the project serves as a global infrastructure that connects banks, payment systems, and individuals to expand financial access to underserved populations. Its main value proposition lies in providing a bridge between traditional money and digital networks through the use of Anchors, which are trusted entities that hold deposits and issue credits on the ledger.  The network operates using the Stellar Consensus Protocol and a Federated Byzantine Agreement, where nodes choose trusted sets of other nodes to agree on the state of the ledger. This system ensures high throughput and fast finality, where transactions are considered permanent and irreversible within seconds. Key features include a built-in distributed exchange for trading assets without intermediaries and the Soroban platform for developing smart contracts. Users can also utilize the network for tokenizing real-world assets or accessing decentralized finance services like peer-to-peer lending.  Stellar's native token, XLM, is essential for maintaining network integrity by acting as an intermediary to find efficient exchange paths and preventing spam through small transaction fees and minimum account balance requirements. Unlike many other digital assets, the network has no inflation because the community voted to disable the automatic creation of new tokens. While the project received early funding from the payments company Stripe, it is now sustained by a global community of validators and developers rather than traditional venture capital.

Stellar Lumens

XLMs price rebound has traders debating whether the move can hold and develop into a breakout, while skeptics point to repeated fade-outs and Bitcoin-driven trading. Bulls tie their optimism to Stellars potential role in institutional payments and tokenization, including DTCC-related adoption, though some of those claims remain speculation.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Strong competitor updates in wet AMD, especially Kodiaks late-stage results, coincided with a sharp selloff in OCUL and renewed debate over AXPAXLIs competitive position. Bullish traders argue differences in trial dosing and AXPAXLIs durability preserve its advantage, while skeptics see the data as raising the competitive bar.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBARs sharp rally and surging volume are being linked by traders to Hederas enterprise-AI story, particularly IBM-related agent identity integration and Hedera council members joining NVIDIAs agent-safety initiative. The reaction is mostly bullish, with talk of a breakout or short squeeze, but some traders say the catalyst is unclear and expect profit-taking or a pullback.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCN is drawing attention as traders debate its weak, choppy price action despite broader crypto strength and Zebecs payroll, card and payments partnerships. Bulls point to adoption, staking and buybacks as reasons to accumulate, while skeptics say usage and token demand remain unproven and the large supply weighs on the outlook.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is drawing attention amid sharp swings and trader backlash over Arthur Hayes reportedly selling after publicly touting the token; some blame his exit for the weakness, while others point to broader crypto volatility. Bulls continue to cite the proof-of-human use case and Grayscale ETF speculation, though an ETF filing is not an approval.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

These Stocks are Refusing to Cool Off

The closing bell is shaping up to be anything but quiet for these names that stand out as the session heads toward the finish. Greenland Energy Company (NASDAQ:GLND), NeOnc Technologies Holdings (NASDAQ:NTHI), GRAIL (NASDAQ:GRAL), Warby Parker (NYSE:WRBY), Montauk Renewables (NASDAQ:MNTK), Ginkgo Bioworks Holdings (NYSE:DNA), and CareDx (NASDAQ:CDNA).

Thursday's ETF Movers: ARKG, TAN

In trading on Thursday, the ARK Genomic Revolution ETF is outperforming other ETFs, up about 2.6% on the day. Components of that ETF showing particular strength include shares of Caredx, up about 13.5% and shares of Twist Bioscience, up about 10.6% on the day.

And underperform...

Zacks.com featured highlights include CareDx, Ciena, Celestica, Materion and MACOM Technology Solutions

CareDx, Ciena, Celestica, Materion and MACOM Technology Solutions pass a screen focused on efficiency measures and earnings surprises.

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently

CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates for CareDx and BillionToOne tests.read more...

5 Top-Ranked High-Efficiency Stocks With Strong Profit Potential

Five stocks stand out for high efficiency, with strong receivables, asset, inventory and operating margin metrics.

4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike

AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.

Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks

COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.

Are Medical Stocks Lagging  CareDx (CDNA) This Year?

Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.

CareDx (CDNA) is a Great Momentum Stock: Should You Buy?

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Caredx Inc

SNOW, CDNA Stocks Hit Fresh 52-Week Highs – What’s Driving Investor Optimism Today?

Equity

Neutral Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Microsoft Corp

Meta Platforms Inc

SELLAS Life Sciences Group Inc

Alphabet Inc Class A

CoreWeave Inc

SpaceX

Stocktwits Polls

$CDNA just keeps on trucking. 
 
1 of our top performing ideas over the last few months despite the market chop. 
 
It's now a double from $26 Buy Point. 
 
Our target (best case) remains $100 but tricky buying up here.

Sammy McCallum

$CDNA — Medicare coverage affirmation and strong revenue growth drove CareDx's recent analyses, alongside technical uptrend signals. 
 
Supportive points: Medicare finalized Local Coverage Determination for solid organ transplant molecular testing. Significant year-over-year quarterly revenue growth reported. 
 
Concerns raised: RSI and MFI nearing overbought territory, suggesting potential short-term overvaluation. Historical periods of operating losses and volatile net income. 
 
Recent analyses for CDNA focused on the significant positive impact of Medicare's finalized Local Coverage Determination for solid organ transplant molecular testing, which served as a key catalyst. The reports also covered substantial year-over-year quarterly revenue growth and a strong technical uptrend indicated by moving averages and momentum indicators. Upcoming second quarter 2026 financial results were noted as a key event to watch.

Andrii Hrytsyshyn

$CDNA 
 
CareDx continues to look strong. 
 
As long as it holds the ~$47 area, the setup remains constructive. Strong price action so far.

Kir Royal

🚨 $CDNA JUST DELIVERED! 🧬☢️

$60 16 OCT 26 CALL 100
$1.00 ➡️ $4.30 🤑

🔥 330% GAINER!

Another setup executed exactly as planned. This is why we stay disciplined, follow the levels, and let the trade work. 📈

LOCK IN. STAY DISCIPLINED. ☢️

PrimeOption Trade

$CDNA adding another +15% today. 
 
It's a stock pickers market just now... over-thinking global macro and major indexes probably isn't helping. 
 
Each chart on its own merits.

$CDNA Trynna establish itself above $50. I think the real move starts once this clears out $60 and into the next earnings report which is 2 months out.

Mr10x

$CDNA  nice reco today---Canaccord initiated coverage of CareDx with a Buy rating and $65 price target, one of the better actors out there

CDNA Caredx Inc